Helsinn Healthcare S.A. v. Ben Venue Laboratories, Inc. (d/b/a Bedford Laboratories)

I'll research this case thoroughly before drafting.

Case overview and background

The parties. Helsinn Healthcare S.A. is a Lugano, Switzerland-based, family-controlled pharmaceutical group and an operating company, not an NPE/PAE — it holds NDA No. 021372 for Aloxi® (palonosetron hydrochloride injection), the 5-HT₃ receptor antagonist it licensed in from Roche/Syntex and launched in the U.S. in 2003 for chemotherapy-induced nausea and vomiting (CINV); it later marketed Akynzeo® as well. Its co-plaintiff was Roche Palo Alto LLC, successor to Syntex (U.S.A.) Inc. and co-owner/licensor of the palonosetron intellectual property; Roche Palo Alto's Rule 7.1 disclosure in the case traced its parents to Roche Holding and identified Novartis as an affiliate (D.I. 1, Sept. 25, 2013, via RPX Insight). The defendant, Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories, was a Bedford, Ohio contract manufacturer of sterile injectables and a member of the Boehringer Ingelheim group (Rule 7.1 disclosure identifying Boehringer Ingelheim Corporation as parent); Bedford was its U.S. generic-injectables commercial arm. Notably, this was an originator-vs.-generic-filer Hatch-Waxman suit, not a patent-assertion-entity campaign.

Accused product and patents. Helsinn and Roche Palo Alto sued under 35 U.S.C. § 271(e)(2) over Ben Venue's ANDA No. 205048, which sought approval for a generic 0.25 mg/5 mL palonosetron hydrochloride intravenous solution — a generic copy of Aloxi® — with a Paragraph IV certification; Bedford's notice letter was dated Aug. 13, 2013, and the complaint records a 30-month stay deadline of Feb. 16, 2016 and patent expiry of Jan. 30, 2024 (D.I. 1). The complaint as filed asserted four patents and was amended twice as new continuations issued, ultimately covering U.S. Patent Nos. 7,947,724, 7,947,725, 7,960,424, 8,518,981, 8,598,218 and 8,598,219, with the '094 patent (8,729,094) added by stipulation in mid-2014. All are members of the same "Liquid Pharmaceutical Formulations of Palonosetron" family (priority to U.S. Provisional 60/444,351, filed Jan. 30, 2003). The '725 patent — the patent your case metadata flags as the patent at issue — claims a pharmaceutically stable aqueous solution of 0.03–0.2 mg/mL palonosetron HCl in a sterile injectable carrier at pH 4–6, with mannitol as tonicifier and 0.005–1.0 mg/mL EDTA, for reducing emesis or the likelihood of emesis; claim 2 narrows this to 0.05 mg/mL at pH 4.5–5.5 with 10–80 mg/mL mannitol and is the claim the Federal Circuit later identified as the asserted claim of the '725. Sourcing caveat: the public docket and secondary databases list the whole family for this case, not the '725 alone, and I could not retrieve the complaint's claim-by-claim assertion list; treat the single-patent framing in the case metadata as a summary rather than a docket-exact statement of the asserted claims.

Posture, venue, and why it matters. Filed Sept. 25, 2013 in the District of Delaware, Case No. 1:13-cv-01612-GMS before Chief Judge Gregory M. Sleet, with Magistrate Judge Mary Pat Thynge handling scheduling/ADR, and consolidated for pretrial purposes with Helsinn's parallel D. Del. ANDA actions (notably Civ. No. 13-688-GMS against Cipla and Aurobindo). Delaware was a natural forum: Ben Venue was a Delaware corporation (expressly pleaded as a basis for personal jurisdiction), and Helsinn had already concentrated its palonosetron ANDA wave there (13-688, 13-1612, 13-2101, 14-427) while litigating separately against Teva, Sandoz and Dr. Reddy's in D.N.J. Ben Venue answered and counterclaimed for invalidity and non-infringement (Oct. 30, 2013) and the parties engaged in claim-construction briefing in spring/summer 2014. The case then took an unusual turn driven by Ben Venue's real-world collapse: after ceasing generic injectable production at Bedford at the end of 2013 amid manufacturing-quality problems and selling the Bedford business to Hikma in May 2014 (Contract Pharma, May 28, 2014), Ben Venue divested ANDA No. 205048 effective July 15, 2014, and by stipulated order Eurohealth International Sarl and West-Ward Pharmaceutical Corp. were substituted as defendants and Ben Venue was dismissed without prejudice (Stip. & Order to Substitute Parties, 13-688-GMS D.I. 99, filed Oct. 17, 2014 — the reason CourtListener now captions the docket "Helsinn Healthcare SA v. Eurohealth International Sarl"). The action terminated Oct. 27, 2015, with the FJC IDB recording the disposition as "Settled"; the settlement terms are not public.

Its significance is largely derivative but substantial: this case was one strand of the 2011–2015 Aloxi® generics cluster that determined when generic palonosetron could launch in a CINV market long dominated by 5-HT₃ antagonist generics. More importantly, the '725 patent asserted here was one of the patents invalidated in the parallel Teva litigation — the Federal Circuit held claims 2 and 9 of the '724, claim 2 of the '725, claim 6 of the '424 and claims 1, 2 and 6 of the '219 invalid under the on-sale bar based on Helsinn's 2001 license and supply agreements with MGI Pharma (Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017)), a judgment affirmed in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 586 U.S. 731 (2019), which held that the AIA did not abrogate the "secret sale" branch of the on-sale bar. That ruling, not anything decided in Delaware, is what makes this docket cite-worthy; it is also why the Delaware case's settlement value collapsed over time. Unexplained/unverified: I did not find a PTAB proceeding challenging the '725 itself (IPR2015-01554 and PGR2016-00007/-00008 targeted sibling patents '094 and '942), and I could not verify the precise dismissal/settlement papers behind the Oct. 27, 2015 termination — both points should be confirmed against PACER before being asserted.

Research memo — Helsinn Healthcare S.A. v. Ben Venue Labs., Inc. (D. Del. No. 1:13-cv-01612-GMS)

Important framing note. Two things about this docket must be stated up front, because they shape everything below:

1. The docket had two lives. It was filed against Ben Venue/Bedford, but Ben Venue divested ANDA No. 205048 in July 2014 and the case caption was formally re-styled Helsinn Healthcare SA v. Eurohealth International Sarl after Eurohealth International Sarl and West‑Ward Pharmaceutical Corp. were substituted as defendants. CourtListener and DrugPatentWatch therefore list this docket under the Eurohealth name.
2. It was not litigated as a standalone case. On 2014‑06‑17 it was consolidated "for all purposes" with C.A. Nos. 13‑688 (Aurobindo/AuroMedics), 13‑2101 (Accord), and 14‑427 (Cipla), with all papers filed in 13‑688‑GMS. From that point, the substantive claim construction and pretrial work happened on the consolidated docket, not on 13‑1612 itself.

Case metadata is consistent with the docket: terminated 2015‑10‑27, Judge Gregory M. Sleet, no jury demand, § 271(e)(2) ANDA case.

---

1. Filing and initial pleadings

I'll research the counsel of record for Helsinn Healthcare in this D. Del. matter.

Let me pull the actual docket and related filings.

I'll research the docket and counsel appearances for this case.

Good leads. Let me pull the actual docket and filings for 13-1612.

Let me get the docket sheet and the Ben Venue answer's signature block.

Counsel of Record — Defendant Ben Venue Laboratories, Inc. (d/b/a Bedford Laboratories)

Helsinn Healthcare S.A. v. Ben Venue Labs., Inc., C.A. No. 1:13-cv-01612-GMS (D. Del.)

Bottom line

The only defendant-side counsel I can verify from the record are the Delaware counsel from Shaw Keller LLP in Wilmington. Counsel appeared through Delaware counsel of record, with an (as-yet-unconfirmed) out-of-state "of counsel" firm behind them. Because this case was consolidated for pretrial purposes with the related Helsinn ANDA cases (notably C.A. No. 13-688-GMS, Helsinn v. Aurobindo), the signature blocks in the consolidated filings are the best available evidence of who represented Ben Venue.

Verified counsel

Source: Stipulation and Order to Substitute Parties, D.I. 99 (filed Oct. 17, 2014) in C.A. No. 13-688-GMS, which bears the consolidated caption including "C.A. No. 13-1612-GMS, Helsinn Healthcare S.A. and Roche Palo Alto LLC v. Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories," and which is signed by "SHAW KELLER LLP /s/ Karen E. Keller … Karen E. Keller (#4489), David M. Fry (#5486) … Attorneys for Defendants Ben Venue, Eurohealth International Sarl, and West-Ward Pharmaceutical Corp."
URL: https://storage.courtlistener.com/recap/gov.uscourts.ded.51743.99.0.pdf

Important caveat — the national/"of counsel" team

That same stipulation contains an "OF COUNSEL" block, but the portion I could retrieve attributes it to the plaintiffs' side (Joseph M. O'Malley, Jr., Bruce M. Wexler, Eric W. Dittmann, David M. Conca, Gary Ji, and Angela C. Ni of Paul Hastings LLP, 75 East 55th Street, New York, and Mark E. Waddell of Loeb & Loeb LLP, New York, for Helsinn/Roche). I could not retrieve the corresponding defense-side "OF COUNSEL" designation for Ben Venue from publicly available text of the filings — the PDF text truncated at that point, and Ben Venue's Answer and Counterclaims (Feb. 24, 2014) and its claim-construction briefs (Opening, Apr. 17, 2014; Answering, July 8, 2014) are not available in full text through the sources I could reach.

I am not going to name a lead trial firm or in-house counsel for Ben Venue without a document. That slot should be filled from the actual signature blocks on: (1) Ben Venue's Answer and Counterclaims to Amended Complaint (Feb. 24, 2014) in C.A. No. 13-1612; (2) Ben Venue's Opening Claim Construction Brief (Apr. 17, 2014); and (3) the Rule 7.1 disclosure statement — all of which would carry the full "OF COUNSEL" listing.

Procedural notes relevant to the counsel picture

• Substitution of parties: Effective July 15, 2014, Ben Venue divested ANDA No. 205048; Eurohealth International Sarl became owner and West-Ward Pharmaceutical Corp. its U.S. agent. By the October 2014 stipulation, Eurohealth and West-Ward were substituted for Ben Venue, and Ben Venue was dismissed without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(ii). Shaw Keller continued as Delaware counsel for the substituted defendants.
• Consolidation: 13-1612 was consolidated with C.A. No. 13-688-GMS and related Helsinn palonosetron ANDA cases before Judge Gregory M. Sleet (the "GMS" suffix), which is why Ben Venue's claim construction papers were filed under the 13-688 docket.
• Patents actually asserted: Although this database lists only the '725 patent, the Second Amended Complaint in 13-1612 asserted U.S. Patent Nos. 7,947,724, 7,947,725, 7,960,424, 8,598,219, and 8,729,094, with the '981 patent added earlier by amendment.
• Termination: The case terminated October 27, 2015 (settled/dismissed); I did not locate a public settlement term sheet, and any such terms would likely not be of record.
• Note the historical throughline: the Helsinn palonosetron family later produced the Supreme Court's on-sale bar decision in Helsinn Healthcare S.A. v. Teva Pharms. USA, Inc., 586 U.S. 731 (2019) — but that case arose from the D.N.J. Teva action, not from this Ben Venue matter. This Delaware action did not generate a merits opinion on the '725 patent that I could locate.

What to pull next (to complete the roster)

1. D.I. 1–30 in C.A. No. 13-1612 on PACER — notices of appearance and the Rule 7.1 statement (identifies both local and national counsel).
2. Ben Venue's Answer & Counterclaims (Feb. 24, 2014), C.A. No. 13-1612 — signature block lists Delaware counsel plus the "OF COUNSEL" firm.
3. Any pro hac vice motions in 13-1612 — these name the out-of-state lead attorneys and their firms directly.

If you want, I can draft the PACER pull list with specific docket-entry targets, or attempt a second pass against the D. Del. docket via a different index to nail down the "OF COUNSEL" firm.